Published in
Elsevier, Clinical Lung Cancer, 5(23), p. e325-e329, 2022
DOI: 10.1016/j.cllc.2022.04.005
Links
Tools
Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer
Journal article published in 2022 by
Andreas Rimner,
Wei-Chu Victoria Lai,
Raffaele Califano,
Salma K. Jabbour,
Charles M. Rudin,
Corinne Faivre-Finn,
Byoung Chul Cho 
,
Terufumi Kato,
Jinming Yu,
Wyatt Chafin,
Li Yu,
Bin Zhao,
Lauren Byers
,
Terufumi Kato,
Jinming Yu,
Wyatt Chafin,
Li Yu,
Bin Zhao,
Lauren Byers
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 